Nourianz
Generic name: istradefylline
Treatment for: Parkinson's Disease
Submission of NDA for Istradefylline (KW-6002), an Investigational Anti-Parkinson's Disease Drug
TOKYO, April 26, 2007 /PRNewswire-FirstCall/ -- Kyowa Hakko Kogyo Co., Ltd. (President: Dr. Yuzuru Matsuda) announced that Kyowa Pharmaceutical, Inc. (New Jersey, United States, President: Shigeru Kobayashi), its wholly owned U.S subsidiary, submitted on April 25, 2007 a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for Istradefylline (KW-6002), its investigational drug for Parkinson's disease.
Parkinson's disease is a progressive neurodegenerative disorder which is characterized by motor symptoms such as slowness of movement, rigidity, tremor and postural instability. The symptoms of this disease result from the progressive degeneration of certain nerve cells located in a specific area in the brain leading to a shortage of the neurotransmitter dopamine. This results in decreased activation of dopamine receptors in the brain which is thought to cause the motor symptoms. The symptoms of Parkinson's disease are treated primarily by dopamine replacement therapy with Levodopa or dopamine agonists. Long term therapy with Levodopa is associated with motor complications such as the development of a shortening response to each dose, which is called "wearing-off phenomenon", and involuntary movements.
Phase II and III clinical studies were conducted with Istradefylline (KW- 6002) in Parkinson's disease patients experiencing "wearing-off phenomenon" on treatment with Levodopa alone or Levodopa administered concomitantly with other Parkinson's disease medications. Based on the clinical efficacy and safety data obtained, the company submitted a NDA for Istradefylline(KW-6002) as adjunctive therapy to levodopa/carbidopa for the treatment of idiopathic Parkinson's disease to improve motor function in patients who experience motor response complications.
Istradefylline(KW-6002) is a novel investigational anti-Parkinson's drug that has a specific antagonistic action on the Adenosine A2A receptor in the brain and is expected to provide benefit to patients with Parkinson's disease.
Posted: April 2007
Related articles
- FDA Approves Nourianz (istradefylline) as an Add-On Drug to Treat Off Episodes in Adults with Parkinson’s Disease - August 28, 2019
- Kyowa Kirin Announces FDA Acceptance of Istradefylline (KW-6002) New Drug Application Resubmission in the US - April 4, 2019
- Kyowa Hakko Receives Not Approvable Letter from FDA forIstradefylline (KW-6002) - February 28, 2008
Nourianz (istradefylline) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.